Oxurion NV — Major Shareholding Notification 2023

May 12, 2023

{0}------------------------------------------------

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – May 12, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on May 8, 2023, from Atlas Special Opportunities LLC indicating that as of May 3, 2023, it held 4,335,547 shares of the then outstanding 733,579,250 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 1.

Oxurion received a transparency notification on May 9, 2023, from Atlas Special Opportunities LLC indicating that as of May 5, 2023, it held 11,481,647 shares of the then outstanding 755,762,036 shares, and therefore remained below the threshold (3%) by virtue of acquisition of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

{1}------------------------------------------------

For further information please contact:

Oxurion NV

Tom Graney Chief Executive Officer

Tel: +32 16 75 13 10

" tom.graney@oxurion.com

Michael Dillen Chief Business Officer

________

Tel: +32 16 75 13 10 michael.dillen@oxurion.com US

Conway Communications

Mary T. Conway

mtconway@conwaycommsir.com

ICR Westwicke

Christopher Brinzey

Tel: +1 617 835 9304

Chris.Brinzey@westwicke.com

^1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

{2}------------------------------------------------

ANNEX 1

{3}------------------------------------------------

9) Denominator

733,579,250

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	7,361,778	4,335,547	0	0.59%	0.00%
	TOTAL	4,335,547		0.59%

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on .

Invelope ID: 2C7D01E0-82F0-4953-9ACA-7B75D860A7CD

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	4,335,547	0.59%

..... . . . . . . . . . . . . . . . . .

{4}------------------------------------------------

Adias Special Opportunities LLC is not a controlled entity. | 12 | In case of proxy voting for only one GM | |-----------------------------------

09/05/2023 (DD/MM/YYYY)

Signature Patrick Vancu

Name & capacity Patrick Vance, proxyholder

{5}------------------------------------------------

ANNEX 2

{6}------------------------------------------------

9) Denominator

755,762,036

i Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	4,335,547	11,481,647	0	1.52%	0.00%
	TOTAL	11,481,647		1.52%

1 Envelope ID: 2C7D01E0-82F0-4953-9ACA-7B75D860A7CD

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	11,481,647	1.52%

+

{7}------------------------------------------------

	Atlas Special Opportunities LLC is not a controlled entity
12) In case of proxy voting for	only one GM
Holder		will cease to hold / will hold again	0 voting rights	(DD/MM/YYYY)
13) Additional information
As of 04/05/2023 Atlas Special Opportunit	5,547 shares in Oxurion NV on 03/05/2023. ies LLC held 2,828,340 shares in Oxurion NV. On 05/05 res. Atlas Special Opportunities LLC subsequently sold
Done at	New York
On	09/05/2023	(DD/MMYYYY)
Name & capacity	Patrick Vance, proxyholder	Signatur	- Bockstyred by: Patrick Vance	2

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable